A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy

Table 1

Baseline characteristics of participants with or without conbercept pretreatment.

	Preoperative intravitreal conbercept	Control	value
Number of eyes	54	53
Sex (male)	27 (62.79%)	24 (53.33%)	0.396
Age (y)	48.63 ± 8.24	49.64 ± 8.71	0.576
Systemic profile
Type of diabetes			0.517
1	6 (13.95%)	4 (8.89%)
2	37 (86.05%)	41 (91.11%)
HbA1c at time of surgery	7.90 ± 1.14	7.63 ± 1.24	0.305
Duration of diabetes (y)	16.67 ± 4.53	15.87 ± 4.77	0.418
Systemic hypertension	11 (25.58%)	11 (24.44%)	1.000
Ocular profile
Study eye (left/right)	19/35 (35.19%/64.81%)	21/32 (39.62%/60.38%)	0.692
Previous history of laser	11 (20.37%)	16 (30.19%)	0.272
Lens status (pseudophakic/phakic)	11/43 (20.37%/79.63%)	8/45 (15.09%/84.91%)	0.614
Pathogeny			0.869
Nonclearing vitreous hemorrhage	22 (40.74%)	23 (43.40%)
Diffuse fibrovascular proliferation	27 (50.00%)	24 (45.28%)
Traction retinal detachment	5 (9.26%)	6 (11.32%)
Extent of vitreoretinal adhesion grade			0.604
3	17 (31.48%)	19 (35.85%)
2	19 (35.19%)	21 (39.62%)
1	18 (33.33%)	13 (24.53%)
0	0 (0%)	0 (0%)

HbA1c: glycosylated hemoglobin A1c.